|
Hajime Hiraragi
Vice President, Pathology & Nonclinical Development
Lyell Immunopharma
Seattle, WA
USA
|
Dr. Hajime Hiraragi is an accomplished professional in biopharmaceutical industry with a broad experience and an exceptional track record of success in development of novel biopharmaceuticals. Dr. Hiraragi is currently Vice President, Pathology & Nonclinical Development at Lyell Immunopharma, Inc., a clinical-stage biotechnology company focusing on developing a curative, next-generation adoptive T cell therapies for patients with solid cancers. As one of the founding members of the company and with his expertise in pathology and toxicology, Dr. Hiraragi leads target variation, regulatory nonclinical development strategy, and safety assessment of Lyell’s novel investigational cell therapy products.
Prior to joining Lyell, Dr. Hiraragi worked at Amgen Inc., as a Director of Pathology in its Research and Translational Sciences organizations, supporting development of discovery research and early-stage development projects in multiple therapeutic areas, targets, and modalities. Prior to his career at Amgen, Dr. Hiraragi was a Pathologist/Scientist at Genentech, Inc., in its Safety Assessment department, serving as a project pathologist as well as a pharmacology team leader for numerous R&D projects.
Dr. Hiraragi obtained his D.V.M. degree from University of Minnesota-Twin Cities, and Ph.D. in molecular pathology from the Ohio State University. He has also completed a residency training in anatomic pathology and is a diplomate of the American College of Veterinary Pathologists (ACVP). He is also board-certified in general toxicology by the American Board of Toxicology (ABT), and has M.B.A from Foster School of Business at University of Washington. He is an active member of Society of Toxicologic Pathology, Society of Toxicology, American College of Veterinary Pathologists, and American Association of Cancer Research. His current focus and interests are development of novel, genetically engineered or non-genetically modified cell therapy products by applying innovative, fit-for-purpose pathology and toxicology approaches.